HR-Positive/HER2-Negative Metastatic Breast Cancer: Unmet Needs, Emerging Data, and Future Directions

Dr. Adam Brufsky concludes the discussion by asking the panel to reflect on the most significant unmet needs in the management of HR-positive/HER2-negative metastatic breast cancer and the future direction of the field. Dr. Virginia Kaklamani, Dr. Rebecca Shatsky, and Dr. Rita Nanda highlight ongoing challenges in defining endocrine resistance, identifying patients who are unlikely to benefit from endocrine-based therapies, and improving treatment options for patients without actionable biomarkers. The faculty emphasize the need for more precise biomarkers to better guide treatment selection and avoid exposing patients to ineffective therapies. The panel also discusses emerging clinical data presented at ASCO 2026 and identifies studies that may influence future treatment standards. In their closing remarks, the experts reflect on the substantial progress that has been made in extending survival and expanding treatment options for patients with HR-positive/HER2-negative metastatic breast cancer. The discussion concludes with a focus on improving tolerability, quality of life, and supportive care while continuing to advance personalized treatment strategies.